MLN Defends Use Of Banned AIDS Drug
MLN Laboratories, the Zambian manufacturers of herbiron tinasiferon, theanti-AIDS drug banned earlier this year (Marketletter April 7), are insisting on the efficacy of the drug which it says is now in great demand.
The agent, developed by MLN's founder, Mulenga Lukwesa, was marketed even after the ban because of high demand and Dr Lukwesa said the company was even considering a price increase because of the demand. A course of 90 capsules over 30 days costs $150.
MLN has released a report based on analysis of the drug by US doctors which the company claims recommends the drug. Two of its main components, viscotoxin and vincristine, have reportedly been used in the USA with good results in AIDS cases. However, the Zambian Ministry of Health has called for further tests by the World Health Organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze